Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIlogy-7: Ramantamig plus daratumumab versus investigator's choice DVRd or DRd in transplant-ineligible newly diagnosed multiple myeloma
jRCT2071260101Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2027
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of ramantamig and daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and 12-month MRD-negative complete response rate. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ramantamigdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071260101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260101.